IASO Bio Secures BLA Approval for Fucaso Therapy
IASO Biotechnology, affectionately known as IASO Bio, is making headlines in the biopharmaceutical industry. The company recently received the much-anticipated Biologics License Application (BLA) approval from the Hong Kong Department of Health for its innovative anti-BCMA CAR-T therapy, Fucaso (Equecabtagene Autoleucel). This groundbreaking therapy is specifically intended for adult patients battling relapsed or refractory multiple myeloma who have undergone at least three treatment lines, including both a proteasome inhibitor and an immunomodulatory agent. The approval highlights IASO Bio's commitment to advancing treatment options in hematologic malignancies.
A Pioneering Milestone in China
This marks an unprecedented achievement as Fucaso is the first CAR-T cell therapy developed in China to gain authorization in Hong Kong. Additionally, it is recognized as the first Advanced Therapy Medicinal Product (ATMP) from China to obtain the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) certification following a thorough inspection by the Hong Kong Department of Health. This recognition is vital as it confirms the quality and safety standards expected of innovative therapies.
Regulatory Pathway and Insights
The BLA approval process involved the novel '1+' innovative regulatory mechanism. This specific pathway took into account prior approvals of Fucaso in Mainland China, alongside robust clinical evidence collected from the FUMANBA-1 registrational study. The Hong Kong Department of Health conducted an independent and detailed assessment of the submitted data spanning quality, nonclinical, clinical, and manufacturing aspects.
Expanding Access to Life-Saving Treatments
In November 2024, Fucaso became accessible in Hong Kong via the Named Patient Programme (NPP). With this recent approval, IASO Bio has exciting plans to expand its operational model, stating, "Manufactured in Nanjing, Supplied Globally." This strategic move aims to facilitate the delivery of this innovative therapy to patients in various regions, maintaining compliance with local regulatory requirements and ensuring treatment availability.
Company Perspectives and Commitment
Ms. Jinhua Zhang, the visionary Founder, Chairperson, and CEO of IASO Bio, expressed her views regarding this pivotal moment for the company. She stated, "This approval in Hong Kong signifies a significant milestone in our global strategy. We are thankful for the rigorous review process by the Hong Kong Department of Health and appreciate the transparency of the '1+' pathway. Our dedication to maintaining high standards of quality, patient safety, and global regulatory collaboration remains unshaken." This input reflects the company’s ethos and dedication to advancing innovative therapies.
Global Registration Progress for Fucaso
With the BLA approved in Hong Kong, Fucaso is making strides globally. The following highlights the registration status of Fucaso across various regions:
- Mainland China: BLA approved by the National Medical Products Administration (NMPA) in June 2023.
- Macau, China: BLA approved in March 2025 by the Macau Pharmaceutical Administration Bureau.
- Hong Kong: BLA approved in November 2025 by the Hong Kong Department of Health.
- Singapore and Saudi Arabia: BLA currently under review.
- South Korea: Awarded Orphan Drug Designation and ATMP Fast Track status.
- Japan: Clinical Trial Notification has been approved.
- Other regions: Continued efforts are underway for registration approval.
Understanding Multiple Myeloma
Multiple myeloma, a hematological malignancy, has seen its global annual incidence rise significantly, from approximately 164,300 cases in 2019 to a projected figure nearing 273,600 by 2040. In China alone, reported cases increased from 28,100 in 2019 to about 31,800 in 2024. Alarmingly, an estimated 30-40% of these patients may need to transition to third-line therapies as their condition progresses. This paints a clear picture of the demand for effective treatment options like Fucaso.
About IASO Bio
Established in 2017, IASO Bio stands as one of the pioneering commercial-stage biopharmaceutical companies in the advanced therapy medicinal product (ATMP) sector. They have an ambitious mission to bring transformative innovations from China to the global healthcare market, aimed specifically at treating hematologic malignancies and autoimmune diseases. With industry-leading, fully integrated platforms that encompass the entire lifecycle of a product—from discovery and development to manufacturing and commercialization—IASO Bio is on a remarkable journey, representing the forefront of therapeutic advancements.
Frequently Asked Questions
What is Fucaso and its purpose?
Fucaso (Equecabtagene Autoleucel) is an anti-BCMA CAR-T therapy intended for patients with relapsed or refractory multiple myeloma.
Who developed Fucaso?
Fucaso was developed by IASO Biotechnology, a biopharmaceutical company focused on innovative cell therapies.
What recent regulatory approval did Fucaso receive?
Fucaso recently received BLA approval from the Hong Kong Department of Health.
How does the approval impact access to Fucaso?
The approval allows IASO Bio to enhance access to Fucaso for patients in Hong Kong and potentially other regions.
What are IASO Bio's future goals?
IASO Bio aims to expand its global outreach and provide innovative cell therapies to more patients worldwide.
